Advertisement
Organisation › Details
Alloy Therapeutics Inc.
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Alloy’s lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Alloy is headquartered in Boston, MA with labs in Cambridge, UK; Basel, CH; San Francisco, CA; and Athens, GA. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation. *
Start | 2017-01-01 established | |
Group | Alloy Therapeutics (Group) | |
Industry | ATX-Gx™ mouse platform | |
Industry 2 | transgenic mouse antibody technology | |
Person | Anderson, Errik (Biomatics Capital 201811– Venture Partner + Alloy Therapeutics before Adimab + Compass Therapeutics) | |
Street | 44 Hartwell Avenue | |
City | 02421 Lexington, MA | |
Address record changed: 2021-12-09 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Alloy Therapeutics. (12/9/21). "Press Release: Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering". Boston, MA & Basel. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Alloy Therapeutics (Group)
- [1] Alloy Therapeutics. (12/9/21). "Press Release: Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering". Boston, MA & Basel....
- [2] Evotec SE. (12/21/20). "Press Release: Evotec Partners with Alloy Therapeutics to Expand Its Antibody Discovery Platform". Hamburg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top